Skip to content
World of Video Gaming – Lifestyle
Home
Sample Page
Author:
Persica Pharmaceuticals
Persica Pharmaceuticals publishes new analyses of antibiotic exposure-response, reinforcing the scientific case for PP353 in vertebrogenic Lumbar Back Pain
September 4, 2026
Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
July 24, 2026
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
March 23, 2026
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
March 19, 2026